Company Profile

CombiPhos Catalysts,Inc.

CombiPhos Catalysts, Inc. operates as a catalytic technology based company worldwide. The company operates in three segments: Novel Homogeneous Catalysts developed from DuPont combinatorial catalysis technologies, Pharmaceutical Intermediates derived from novel cross-coupling reactions and homogeneous catalysis, and Deuterium Drug Discovery through patented various catalytic H/D exchanges and C-D cross-coupling reactions.

The Novel Homogeneous Catalysts segment provides a wide variety of highly active, air- and moisture-stable homogeneous catalysts (POPd, POPd1, POPd2, POPd3, POPd4, POPd5, POPd6, POPd7, PXPd, PXPd2, PXPd2-Br, PXPd3, PXPd4, PXPd6, PXPd7, CombiPhos-Pd6, and CombiPhos-Kit) for various cross-coupling reactions, which are made with technology licensed from DuPont.

Pharmaceutical Intermediates segment discovers, develops, manufactures, and markets “historically unstable” chemical intermediates (gram to kg scale) including derivatives of pyridine-2-boronic acids, pyridine-4-boronic acids, thiazole-4-boronic acids, thiazole-5-boronic acids, pyrazole-3-boronic acids, pyrazole-4-boronic acids, imidazole-4-boronic acids, pyrimidine-5-boronic acids, pyrazine-2-boronic acids, thiophene-2-boronic acids, furan-2-boronic acids, pyridazine-4-boronic acids, and triazole-4-boronic acids, via novel catalytic transformations.

CombiPhos Catalysts, Inc. has supplied these novel homogeneous catalysts and intermediates to a wide variety of pharmaceutical companies for drug discovery and development, which include Pfizer, Merck, Novartis, GSK, Sanofi Aventis, AstraZeneca, J&J, BMS, Abbvie, Eli Lilly, Amgen, Gilead, Takeda, Celgene, Genentech, Biogen Idec, Boehringer Ingelheim, Bayer, Lundbeck, Vertex, Roche, etc.

The Company’s Deuterium Drug Discovery segment discovers and develops innovative deuterium-containing small molecule drugs through application of its patented and/or licensed homogenous catalysis technologies gained from years of know-how with these catalysts in the cross-coupling reactions of C-C, C-B, C-N, C-S, C-O, and C-D bond formation, as well as C-H bond activation.  CombiPhos focuses its efforts on selecting approved drugs and drugs in later-stage clinical trials that can only be deuterated using catalytic technology and whose structures are amenable to deuteration.  Using its patented processing technology CombiPhos is capable of selectively substituting hydrogen atoms with deuterium atoms to optimize the activity of the selected drug and, importantly, is able to produce these deuterated drugs with purity levels or 99% or more to avoid obviousness patent issues. This deuteration process has the potential to produce drugs that possess better pharmacokinetic and/or metabolic properties, toxicity profile with resultant enhanced clinical safety, tolerability and efficacy.        

CombiPhos Catalysts, Inc. was founded in 2001 and is based in Princeton, New Jersey.